SAGE - Sage Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
167.09
-1.47 (-0.87%)
As of 10:05AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close168.56
Open168.08
Bid167.23 x 100
Ask167.69 x 200
Day's Range166.10 - 168.08
52 Week Range59.57 - 195.97
Volume17,661
Avg. Volume529,531
Market Cap7.772B
Beta3.74
PE Ratio (TTM)N/A
EPS (TTM)-7.22
Earnings DateJul 30, 2018 - Aug 3, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est208.86
Trade prices are not sourced from all markets
  • Amazon fuels T. Rowe Price U.S. mutual funds past the S&P 500
    American City Business Journals1 hour ago

    Amazon fuels T. Rowe Price U.S. mutual funds past the S&P 500

    Baltimore-based mutual fund giant T. Rowe Price has been arguing over the last few years that during times when the stock market isn't steadily rising, its actively managed mutual funds would outperform passively managed funds that mirror indexes.

  • How to build a winning stock portfolio, and seven stocks to get you started
    MarketWatch5 days ago

    How to build a winning stock portfolio, and seven stocks to get you started

    Tom Vandeventer of the Tocqueville Opportunity Fund says it’s worth paying up for cloud-based services companies including ServiceNow, Nutanix and Workday.

  • Sage Therapeutics’ NMDA Receptor–Based Products
    Market Realist7 days ago

    Sage Therapeutics’ NMDA Receptor–Based Products

    Sage Therapeutics (SAGE) is focused on the development of the products for the treatment of life-threatening central nervous system (or CNS) disorders. One of the products under development, SAGE-718, is based on its NMDA Receptor program.

  • Sage Therapeutics’ Product Portfolio in July
    Market Realist10 days ago

    Sage Therapeutics’ Product Portfolio in July

    Sage Therapeutics’ (SAGE) product portfolio includes products under development for the treatment of various rare and life-threatening central nervous system disorders. The chart below shows the products under development, based on the drug discovery programs for Sage Therapeutics. The company classifies its products into two programs: GABA receptors and NMDA receptors. 

  • Sage Therapeutics: Analysts’ Estimates and Recommendations
    Market Realist10 days ago

    Sage Therapeutics: Analysts’ Estimates and Recommendations

    Sage Therapeutics (SAGE) is a clinical-stage biopharmaceutical company. Sage Therapeutics develops medicines for the treatment of life-altering central nervous system disorders such as Parkinson’s disease and postpartum depression.

  • CNBC11 days ago

    Cramer Remix: Investors can't see the reality of this market

    CNBC's Jim Cramer makes the case to value the market just as it is. The "Mad Money" host also hears from the CEOs of Sage Therapeutics and Vistra Energy. In the lightning round, Cramer makes the case for buying shares of World Wrestling Entertainment.

  • 3 Top Biotech Stocks to Buy for the 2nd Half of 2018
    Motley Fool15 days ago

    3 Top Biotech Stocks to Buy for the 2nd Half of 2018

    Consider putting these large-cap, mid-cap, and small-cap biotech stocks on your buy list.

  • ACCESSWIRE17 days ago

    Complimentary Technical Snapshots on Verastem and Three More Biotech Stocks

    Stock Research Monitor: RXII, SAGE, and SGMO LONDON, UK / ACCESSWIRE / July 6, 2018 / If you want a free Stock Review on VSTM sign up now at www.wallstequities.com/registration . This morning, WallStEquities.com ...

  • Business Wire18 days ago

    Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on July 2, 2018, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 129,000 shares of its common stock to 31 new employees under Sage’s 2016 Inducement Equity Plan. The 2016 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Sage (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Sage, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

  • ACCESSWIRE26 days ago

    Today's Research Reports on Trending Tickers: Amicus Therapeutics and Sage Therapeutics

    NEW YORK, NY / ACCESSWIRE / June 27, 2018 / U.S. markets rebounded on Tuesday after experiencing steep losses the past week due to growing trade tensions. The Dow Jones Industrial Average increased 0.12 ...

  • PR Newswire28 days ago

    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Sage Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

    NEW YORK , June 25, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...

  • Trending: Technology Sector Surges to Record Highs Despite Trade Jitters
    ETF Databaselast month

    Trending: Technology Sector Surges to Record Highs Despite Trade Jitters

    Investors have bought into the technology sector with fervor as markets enjoyed a brief period of tranquility just before politicians resumed their belligerent rhetoric.

  • SAGE Therapeutics’ NMDA Receptor–Based Portfolio
    Market Realistlast month

    SAGE Therapeutics’ NMDA Receptor–Based Portfolio

    As discussed, SAGE Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system disorders.

  • SAGE Therapeutics’ GABA Receptor–Based Portfolio
    Market Realistlast month

    SAGE Therapeutics’ GABA Receptor–Based Portfolio

    As we discussed earlier, SAGE Therapeutics’ (SAGE) portfolio includes the products it has under development for the treatment of life-threatening central nervous system disorders based on either GABA (gamma-Aminobutyric acid) or NMDA (N-methyl-D-aspartate) receptor systems.

  • A Look at SAGE Therapeutics’ Product Portfolio
    Market Realistlast month

    A Look at SAGE Therapeutics’ Product Portfolio

    SAGE Therapeutics (SAGE) includes two different programs based on the modulation of GABAA (gamma-Aminobutyric acid) and NMDA (N-methyl-D-aspartate) receptors for the treatment of life-threatening central nervous system disorders. Let’s have a look at the details of these programs.

  • SAGE Therapeutics’ Strategic Collaboration with Shionogi
    Market Realistlast month

    SAGE Therapeutics’ Strategic Collaboration with Shionogi

    On June 13, SAGE Therapeutics (SAGE) announced a strategic collaboration with Shionogi & Company for the development and commercialization of the drug SAGE-217. Let’s take a look at the details of the collaboration.

  • SAGE Therapeutics’ Stock Performance and Estimates in June
    Market Realistlast month

    SAGE Therapeutics’ Stock Performance and Estimates in June

    SAGE Therapeutics (SAGE), a clinical research–based biopharmaceutical company, develops drugs for the treatment of life-threatening central nervous system disorders such as Parkinson’s disease and postpartum depression.

  • Investopedialast month

    Why Biotech Stocks May Reach New Highs

    Biotech stocks are nearing a big break out as measured by the SPDR S&P Biotech ETF ( XBI). The group is already having a strong start to 2018, quietly outpacing not only the S&P 500 but the most talked about sectors in the market, technology ( XLK) and consumer stocks ( XLY). The biotech ETF is sitting right below a significant resistance level at $97.90, the previous all-time high for the ETF, and should that price rise above technical resistance, it would mark a big breakout.

  • MarketWatchlast month

    Sage shares drop 3% after $90 mln Shionogi deal for key drug

    Sage Therapeutics Inc. shares dropped 3.3% in Thursday morning trade after the company announced a $90 million deal with Shionogi & Co. Ltd. for the clinical development and commercialization of its drug SAGE-217 in Japan, Taiwan and South Korea. Shionogi will also handle clinical development, regulatory filings and commercialization of SAGE-217 for major depressive disorder and any other indications in those countries.

  • Business Wirelast month

    Sage Therapeutics and Shionogi & Co., Ltd., Enter Strategic Collaboration to Develop and Commercialize SAGE-217 for MDD and Other Indications in Japan, Taiwan and South Korea

    Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, and Shionogi & Co., Ltd., today announced they have entered into a strategic collaboration for the clinical development and commercialization of SAGE-217 for the treatment of major depressive disorder (MDD) and other indications in Japan, Taiwan and South Korea. Sage received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for SAGE-217 in MDD in February 2018, and recently announced an expedited development plan for SAGE-217 in the U.S. with a pivotal Phase 3 placebo-controlled trial in patients with MDD expected to commence this year, and an ongoing placebo-controlled trial in women with PPD, now also designated a pivotal trial.

  • Biotech Stock Loses Steam, But Analysts Still Bullish On Depression Drug
    Investor's Business Dailylast month

    Biotech Stock Loses Steam, But Analysts Still Bullish On Depression Drug

    Sage Therapeutics lost some of its steam Wednesday, as shares dropped more than 3%, but analysts remained bullish on the biotech company's plans for an acute depression treatment.

  • Company News For Jun 13, 2018
    Zackslast month

    Company News For Jun 13, 2018

    Companies In The News are: TSLA,SAGE,RH,PLAY

  • ACCESSWIRElast month

    Today’s Research Reports on Stocks to Watch: Sage Therapeutics and Galmed Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / June 13, 2018 / It was an exciting day for biotech stocks Sage Therapeutics and Galmed Pharmaceuticals. Sage rose higher after announcing that the FDA has allowed expedited development on its major depressive drug. Shares of Galmed soared to a new high after announcing positive results from its Phase 2b ARREST study.

  • Here's Why Sage Therapeutics Rose as Much as 20.3% Today
    Motley Foollast month

    Here's Why Sage Therapeutics Rose as Much as 20.3% Today

    The FDA approved an accelerated path through the clinic for the biopharma's next major drug candidate.

  • Depression should be treated like a broken leg or a seizu...
    CNBC Videos11 days ago

    Depression should be treated like a broken leg or a seizu...

    Jim Cramer sits down with Sage Therapeutics CEO Jeff Jonas to hear about the novel treatments his company is testing for depression.